Inclusion Criteria:

Eligibility will be determined separately for Part I and Part II of this study:

Part I ( Part I Eligibility criteria (eligibility for undergoing apheresis procedure)

• Age ≤ 25 years at initial diagnosis.
• Must have one of the following diagnoses:
• High risk neuroblastoma
• Metastatic or recurrent retinoblastoma
• High risk rain tumors
• Recurrent or refractory Hodgkin disease
• Recurrent or advanced stage Wilms tumor
• Recurrent or metastatic sarcomas
• Recurrent or refractory non-Hodgkin lymphoma
• Desmoplastic small round cell tumor.
• Lansky or Karnofsky Performance Score ≥ 70.
• Creatinine ≤ 2.0 mg/dl.
• Direct bilirubin ≤ 2.0 mg/dl.
• SGPT ≤ 2 x upper limit of normal
• HIV testing
• Negative pregnancy test
• Patients with significant prior radiation therapy to the liver will be excluded.

Part II eligibility criteria (criteria for transplantation of CD133 select stem cell product)

• Successfully completed Part I of protocol treatment plan and has the following available:
• Stored autologous bone marrow or peripheral blood stem cells (i.e. 2 x 106 unselected CD34+ cells/ kg PBSC or 1 x 106 CD34+ cells/ kg BM) for back up.
• Stored autologous bone marrow or peripheral blood stem cells (2 x 106 CD133+ cells/ kg PBSC or 2 x 106 CD133+ cells/ kg BM) for infusion.
• Forced vital capacity greater than or equal to 40% normal or pulse oximetry greater than or equal to 92% on room air.
• Lansky or Karnofsky Performance Score ≥ 70.
• Creatinine ≤ 2.0 mg/dl.
• Direct bilirubin ≤ 2.0 mg/dl.
• SGPT ≤ 2 x upper limit of normal
• Negative pregnancy test
• Patients with significant prior radiation therapy (in opinion of the PI) to the liver will be excluded.